Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panacea BiotecBOM:531349 -5.43%63 Days Inventory is 117.70 as of Jun. 2026, which is 56% below its 10-year median of 264.73. GuruFocus rates BOM:531349 with a GF Score™ of 63/100 and a GF Value™ of ₹404.95 (Fairly Valued). The stock has 2 warning signs investors should review. Among 638 Biotechnology companies, Panacea Biotec ranks worse than 60.19% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Panacea Biotec's Average Total Inventories for the
three
months ended in Jun. 2026 was ₹1,983 Mil. Panacea Biotec's Cost of Goods Sold for the
three
months ended in Jun. 2026 was ₹1,538 Mil.
Hence, Panacea Biotec's Days Inventory for the
three
months ended in Jun. 2026 was 117.70.
The historical rank and industry rank for Panacea Biotec's Days Inventory or its related term are showing as below:
BOM:531349'
s Days Inventory Range Over the Past 10 Years
Min: 222.25 Med: 264.73 Max: 663.09
Current: 240.08
During the past 13 years, Panacea Biotec's highest Days Inventory was 663.09. The lowest was 222.25. And the median was 264.73.
BOM:531349's Days Inventory is ranked worse than 60.19% of 638
companies
in the Biotechnology industry
Industry Median: 184.675
vs BOM:531349: 240.08
Panacea Biotec's Days Inventory
declined
from Jun. 2025 (153.27) to Jun. 2026 (117.70).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Panacea Biotec's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.78.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Panacea Biotec's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.99.
Panacea Biotec (BOM:531349) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Panacea Biotec's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Panacea Biotec's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Panacea Biotec Days Inventory Related Terms
Panacea Biotec Days Inventory Historical Data
* Premium members only.
The historical data trend for Panacea Biotec's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531349 vs VRTX, REGN, MRNA: Days Inventory Comparison
For the Biotechnology subindustry, Panacea Biotec's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Biotec Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panacea Biotec's Days Inventory distribution charts can be found below:
* The bar in red indicates where Panacea Biotec's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Biotec (BOM:531349) has a Days Inventory of 117.70 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Panacea Biotec and its competitors. This is 56% below median its historical median of 264.73. Over the past decade, Panacea Biotec's Days Inventory has ranged from 222.25 to 663.09. According to the industry distribution chart, Panacea Biotec ranks #384 out of 638 companies in the Biotechnology industry, placing it in the top 60.2%.
Is Panacea Biotec's Days Inventory too high?
Panacea Biotec's current Days Inventory of 117.70 is 56% below median its 10-year median of 264.73. Over the past 10 years, this metric has ranged from a low of 222.25 to a high of 663.09. The Biotechnology industry median Days Inventory is 184.68. Panacea Biotec's value of 117.70 is 36.3% below this industry median. Based on the distribution chart, Panacea Biotec ranks #384 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Panacea Biotec has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panacea Biotec ranks #384 out of 638 companies for Days Inventory. This places Panacea Biotec in the lower half of its industry. The industry median Days Inventory is 184.68. Panacea Biotec's value of 117.70 is 36.3% below this benchmark. Historically, Panacea Biotec's own Days Inventory has ranged from 222.25 to 663.09 over the past decade. While the company's 10-year median is 264.73 vs. the industry median of 184.68, Panacea Biotec has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.68, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Biotec's current Days Inventory of 117.70 is 36.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Panacea Biotec and its competitors. For the Biotechnology industry, the median Days Inventory is 184.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Biotec's current Days Inventory is 117.70, which is 56% below median its own 10-year median of 264.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Fairly Valued. The stock's GF Value™ is ₹404.95, compared to a current price of ₹376.45 — trading 7% below its estimated fair value. The current Days Inventory is 117.70, which is 56% below median its 10-year median of 264.73 and 36.3% below the Biotechnology industry median of 184.68. Panacea Biotec's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Days Inventory is 117.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panacea Biotec (BOM:531349) Overvalued in 2026?
Based on GuruFocus' analysis, Panacea Biotec stock appears to be undervalued.
The current stock price of ₹376.45 is trading 7% below its estimated GF Value™ of ₹404.95.
GuruFocus considers Panacea Biotec to be Fairly Valued.
Key valuation signals for BOM:531349:
Days Inventory: 117.70 (56% below median its 10-year median of 264.73)
GF Value™: ₹404.95 vs. price of ₹376.45 (7% below fair value)
Industry Position: 36.3% below the Biotechnology median (#384 of 638)
No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
63GF Score
Get the complete analysis for BOM:531349
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531349 has been successfully added to your 
